Comments
Pharma major Dr. Reddy’s Laboratories Ltd has launched ‘Versavo (bevacizumab)’, a biosimilar of Roche’s Avastin in India.
The drug is for the treatment of several types of cancers (metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, metastatic breast cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer)..
Dr Reddy’s Versavo is available in strengths of 100mg and 400mg single use vials.
Commenting on the launch, MV Ramana, CEO - India and Emerging Markets, Dr. Reddy’s Laboratories said the launch of Versavo will strengthen Hyderabad -based company's Oncology portfolio.
‘Avastin’ and its biosimilars had India sales of approximately Rs 223 crore for the most recent twelve months ending in December 2018,according to Ipsos.
Dr. Reddy’s now has six biosimilar products commercialised in India and various emerging markets and an active development pipeline of several biosimilar products in the oncology and immunology space.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.